Authors' Affiliations: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Departments of Biotherapy; and Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR ChinaAuthors' Affiliations: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Departments of Biotherapy; and Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Authors' Affiliations: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Departments of Biotherapy; and Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Clin Cancer Res. 2014 Jun 1;20(11):3003-11. doi: 10.1158/1078-0432.CCR-14-0082. Epub 2014 Mar 25.
Triple-negative breast cancer (TNBC) is a high risk form of this disease, even after surgery, due to the absence of targets for hormone treatment and anti-Her-2 therapy. Chemotherapy is the main therapeutic strategy for such patients with breast cancer, although the outcome is often unsatisfactory. Thus, the development of combination adjuvant therapies is essential for improved prognosis in patients with TNBC. In this study, we investigated the efficacy of a sequential combination of cytokine-induced killer cell (CIK) infusion and chemotherapy for patients with post-mastectomy TNBC.
From 2008 to 2012, 90 patients with post-mastectomy TNBC were included in this retrospective study: 45 cases received chemotherapy alone or with sequential radiotherapy; a further 45 cases received chemotherapy with/without radiotherapy and sequential CIK infusion.
Survival analysis showed significantly higher disease-free survival (DFS) and overall survival (OS) rates in the CIK treatment group compared with the control group (P = 0.0382, P = 0.0046, respectively; log-rank test). Multivariate survival analysis showed that CIK adjuvant treatment was an independent prognostic factor for OS of patients with TNBC. In subgroup analyses, CIK adjuvant treatment significantly increased the DFS rate of patients with pathologic grade 3, and significantly increased the OS rate of patients in N1, N2, N3, IIB, III TNM (tumor-node-metastasis) stages, and with pathologic grade 3.
These data indicate that adjuvant CIK treatment combined with chemotherapy is an effective therapeutic strategy to prevent disease recurrence and prolong survival of patients with TNBC, particularly those with lymph node metastasis, advanced TNM stage, and poor pathologic grade. Clin Cancer Res; 20(11); 3003-11. ©2014 AACR.
三阴性乳腺癌（TNBC）是一种高风险形式的这种疾病，即使在手术后，由于缺乏激素治疗和抗 Her-2 治疗的靶点。化疗是此类乳腺癌患者的主要治疗策略，尽管结果往往不尽如人意。因此，开发联合辅助疗法对于改善 TNBC 患者的预后至关重要。在这项研究中，我们研究了细胞因子诱导的杀伤细胞（CIK）输注与化疗联合序贯治疗乳腺癌根治术后 TNBC 患者的疗效。
从 2008 年到 2012 年，90 例乳腺癌根治术后 TNBC 患者纳入本回顾性研究：45 例接受单独化疗或序贯放疗；另外 45 例接受化疗联合/不联合放疗和序贯 CIK 输注。
生存分析显示，CIK 治疗组的无病生存率（DFS）和总生存率（OS）明显高于对照组（P=0.0382，P=0.0046，log-rank 检验）。多变量生存分析显示，CIK 辅助治疗是 TNBC 患者 OS 的独立预后因素。亚组分析显示，CIK 辅助治疗显著提高了病理分级 3 级患者的 DFS 率，显著提高了 N1、N2、N3、IIB、III 期 TNM（肿瘤-淋巴结-转移）和病理分级 3 级患者的 OS 率。
这些数据表明，辅助 CIK 治疗联合化疗是预防疾病复发和延长 TNBC 患者生存的有效治疗策略，特别是那些具有淋巴结转移、晚期 TNM 分期和较差病理分级的患者。临床癌症研究；20(11)；3003-11. ©2014AACR。
